Athenex, a US-China company, out-licensed China commercialization rights for KX2-391, an actinic keratosis/oncology treatment, to Chongqing Jingdong Junzhuo Pharma. Athenex will receive an upfront payment of $14.5 million and milestones of up to $15 million, plus tiered royalties starting at 15%. KX2-391 is a first-in-class dual Src kinase and tubulin polymerization inhibitor; KX2-391 ointment is a topical treatment for actinic keratosis in Phase III development. Athenex will be responsible for China development of the products; Jingdong will be in charge of commercialization.
Source: China Biotoday
